FASL antibody

Catalog No. ABIN1176981

Product Details anti-FASL Antibody

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reactivity: Mouse

Host: Armenian Hamster

Clonality: Monoclonal

Conjugate: This FASL antibody is un-conjugated

Application: Flow Cytometry (FACS), Blocking Reagent (BR)

Brand: BD Pharmingen™

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Sterility: 0.2 μm filtered

Endotoxin Level: Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.

Immunogen: Mouse FasL-transfected cells

Clone: MFL3

Isotype: IgG1 kappa

Application Details

Application Notes: Enriched splenic T cells can be induced to express Fas Ligand by 6-8-hour culture with plate-bound anti-mouse CD3 mAb 17A2 (Cat. No. 555273), mAb 145-2C11 (Cat. No. 557306), or mAb 500A2 (Cat. No. 553238). Because Fas Ligand is expressed at low density on activated cells, it may be desirable to amplify staining by using a biotinylated second-step antibody with a bright third-step reagent, such as PE Streptavidin (Cat. No. 554061). The BD Biosciences anti-hamster IgG mAb cocktails, either biotin- or PE-conjugated (Cat. No. 554010 or 554056, respectively) are not effective for staining with mAb MFL3. Other reported applications include blocking of the cytotoxic activities of the mouse FasLigand-transfected L5178Y T lymphoma and influenza-specific CD8+ BALB/c CTL clones.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.

Preservative: Azide free

Storage: 4 °C

Storage Comment: Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

References for anti-FASL antibody (ABIN1176981)

Hohlbaum, Moe, Marshak-Rothstein: "Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival." in: The Journal of experimental medicine, Vol. 191, Issue 7, pp. 1209-20, (2000) (PubMed).

Fuller, Ravichandran, Braciale: "Phosphatidylinositol 3-kinase-dependent and -independent cytolytic effector functions." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 162, Issue 11, pp. 6337-40, (1999) (PubMed).

Schneider, Holler, Bodmer, Hahne, Frei, Fontana, Tschopp: "Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity." in: The Journal of experimental medicine, Vol. 187, Issue 8, pp. 1205-13, (1998) (PubMed).

Griffith, Ferguson: "The role of FasL-induced apoptosis in immune privilege." in: Immunology today, Vol. 18, Issue 5, pp. 240-4, (1997) (PubMed).

Kayagaki, Yamaguchi, Nagao, Matsuo, Maeda, Okumura, Yagita: "Polymorphism of murine Fas ligand that affects the biological activity." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, Issue 8, pp. 3914-9, (1997) (PubMed).

Griffith, Brunner, Fletcher, Green, Ferguson: "Fas ligand-induced apoptosis as a mechanism of immune privilege." in: Science (New York, N.Y.), Vol. 270, Issue 5239, pp. 1189-92, (1996) (PubMed).

Lau, Yu, Fontana, Stoeckert: "Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice." in: Science (New York, N.Y.), Vol. 273, Issue 5271, pp. 109-12, (1996) (PubMed).

Lynch, Ramsdell, Alderson: "Fas and FasL in the homeostatic regulation of immune responses." in: Immunology today, Vol. 16, Issue 12, pp. 569-74, (1996) (PubMed).

Kojima, Shinohara, Hanaoka, Someya-Shirota, Takagaki, Ohno, Saito, Katayama, Yagita, Okumura: "Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes." in: Immunity, Vol. 1, Issue 5, pp. 357-64, (1995) (PubMed).

Ramsdell, Seaman, Miller, Picha, Kennedy, Lynch: "Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death." in: International immunology, Vol. 6, Issue 10, pp. 1545-53, (1995) (PubMed).

Bellgrau, Gold, Selawry, Moore, Franzusoff, Duke: "A role for CD95 ligand in preventing graft rejection." in: Nature, Vol. 377, Issue 6550, pp. 630-2, (1995) (PubMed).

Brunner, Mogil, LaFace, Yoo, Mahboubi, Echeverri, Martin, Force, Lynch, Ware: "Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas." in: Nature, Vol. 373, Issue 6513, pp. 441-4, (1995) (PubMed).

Ju, Panka, Cui, Ettinger, el-Khatib, Sherr, Stanger, Marshak-Rothstein: "Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation." in: Nature, Vol. 373, Issue 6513, pp. 444-8, (1995) (PubMed).

Suda, Okazaki, Naito, Yokota, Arai, Ozaki, Nakao, Nagata: "Expression of the Fas ligand in cells of T cell lineage." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 154, Issue 8, pp. 3806-13, (1995) (PubMed).

Vignaux, Vivier, Malissen, Depraetere, Nagata, Golstein: "TCR/CD3 coupling to Fas-based cytotoxicity." in: The Journal of experimental medicine, Vol. 181, Issue 2, pp. 781-6, (1995) (PubMed).

Smith, Farrah, Goodwin: "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death." in: Cell, Vol. 76, Issue 6, pp. 959-62, (1994) (PubMed).

Takahashi, Tanaka, Brannan, Jenkins, Copeland, Suda, Nagata: "Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand." in: Cell, Vol. 76, Issue 6, pp. 969-76, (1994) (PubMed).

Target Details for FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Alternative Name: CD178 (FASL Products)

Synonyms: ALPS1B antibody, APT1LG1 antibody, APTL antibody, CD178 antibody, CD95-L antibody, CD95L antibody, FASL antibody, TNFSF6 antibody, fasl antibody, Fas-L antibody, Faslg antibody, Tnfsf6 antibody, gld antibody, Apt1Lg1 antibody, Fasl antibody, FASLG antibody, zgc:162027 antibody, Fas ligand antibody, Fas ligand L homeolog antibody, Fas ligand (TNF superfamily, member 6) antibody, FASLG antibody, faslg.L antibody, Fasl antibody, Faslg antibody, faslg antibody

Background: The MFL3 antibody reacts with CD178 (Fas Ligand, CD95 Ligand) on all strains tested. In the mouse, Fas Ligand is expressed on activated T cell lines and in spleen, testis, and eye. FasL mRNA has been demonstrated at various levels in bone marrow, thymus, spleen, lymph node, lung, small intestine, testis, and uterus. Moreover, T-cell activators, but not B-cell activators, enhanced the expression of FasL mRNA in splenocytes, and FasL mRNA was restricted to the T-cell lineage among a panel of cell lines from lymphoid tissues. Fas Ligand is not functional in mice homozygous for the gld (generalized lympho-proliferative disease) mutation, these mice cannot limit the expansion of activated lymphocytes and develop autoimmune disease. Fas Ligand is a member of the TNF/NGF family, which binds to CD95 (Fas), inducing apoptotic cell death. This Fas/Fas Ligand interaction is believed to participate in T-cell development, the regulation of immune responses, and cell-mediated cytotoxic mechanisms. There is mounting evidence that Fas Ligand is also proinflammatory, mediating neutrophil extravasation and chemotaxis. Fas Ligand is released from the surface of transfectant cells by metalloproteinases, and the soluble Fas Ligand may block the activities of the membrane-bound molecule. The MFL3 mAb has been reported to efficiently inhibit the cytotoxicity of mouse Fas Ligand-transfected cells against human Fas-transfected cells. This hamster mAb to a mouse leukocyte antigen does not cross-react with rat leukocytes.
Synonyms: Fas Ligand, CD95 Ligand

Pathways: Apoptosis, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity